AU2003219805B2 - Electroporation methods for introducing bioactive agents into cells - Google Patents

Electroporation methods for introducing bioactive agents into cells Download PDF

Info

Publication number
AU2003219805B2
AU2003219805B2 AU2003219805A AU2003219805A AU2003219805B2 AU 2003219805 B2 AU2003219805 B2 AU 2003219805B2 AU 2003219805 A AU2003219805 A AU 2003219805A AU 2003219805 A AU2003219805 A AU 2003219805A AU 2003219805 B2 AU2003219805 B2 AU 2003219805B2
Authority
AU
Australia
Prior art keywords
cell
nucleic acid
microparticles
dna
microparticle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003219805A
Other languages
English (en)
Other versions
AU2003219805A1 (en
Inventor
Shikha P. Barman
Mary Lynne Hedley
Daqing Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Inc
Original Assignee
Eisai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Inc filed Critical Eisai Inc
Publication of AU2003219805A1 publication Critical patent/AU2003219805A1/en
Assigned to MGI PHARMA BIOLOGICS, INC. reassignment MGI PHARMA BIOLOGICS, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: ZYCOS, INC.
Assigned to EISAI CORPORATION OF NORTH AMERICA reassignment EISAI CORPORATION OF NORTH AMERICA Request for Assignment Assignors: MGI PHARMA BIOLOGICS, INC.
Application granted granted Critical
Publication of AU2003219805B2 publication Critical patent/AU2003219805B2/en
Assigned to EISAI INC. reassignment EISAI INC. Request for Assignment Assignors: EISAI CORPORATION OF NORTH AMERICA
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0047—Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Electrotherapy Devices (AREA)
AU2003219805A 2002-02-15 2003-02-18 Electroporation methods for introducing bioactive agents into cells Ceased AU2003219805B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35754202P 2002-02-15 2002-02-15
US60/357,542 2002-02-15
PCT/US2003/004937 WO2003070905A2 (en) 2002-02-15 2003-02-18 Electroporation methods for introducing bioactive agents into cells

Publications (2)

Publication Number Publication Date
AU2003219805A1 AU2003219805A1 (en) 2003-09-09
AU2003219805B2 true AU2003219805B2 (en) 2009-06-04

Family

ID=27757633

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003219805A Ceased AU2003219805B2 (en) 2002-02-15 2003-02-18 Electroporation methods for introducing bioactive agents into cells

Country Status (6)

Country Link
US (1) US20040053873A1 (https=)
EP (1) EP1482974A4 (https=)
JP (1) JP2005530695A (https=)
AU (1) AU2003219805B2 (https=)
CA (1) CA2476452A1 (https=)
WO (1) WO2003070905A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002348163A1 (en) * 2001-11-02 2003-05-19 Intradigm Corporation Therapeutic methods for nucleic acid delivery vehicles
US20030198625A1 (en) * 2002-04-19 2003-10-23 Genteric, Inc. Electroporation-mediated transfection of the salivary gland
US8361976B2 (en) 2004-07-09 2013-01-29 University Of Massachusetts Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules
JP4961137B2 (ja) * 2005-12-14 2012-06-27 久光製薬株式会社 イオントフォレーシス用デバイス
GB0602637D0 (en) * 2006-02-09 2006-03-22 Glaxo Group Ltd Novel process
US20090082713A1 (en) * 2007-09-20 2009-03-26 Friden Phillip M Method of enhancing iontophoretic delivery of a peptide
DE102009028462A1 (de) * 2009-08-11 2011-03-24 Leibniz-Institut für Plasmaforschung und Technologie e.V. Vorrichtung und Verfahren zur Behandlung von lebenden Zellen mittels eines Plasmas
WO2011057137A1 (en) 2009-11-05 2011-05-12 Neuronexus Technologies Waveguide neural interface device
WO2012024526A2 (en) * 2010-08-20 2012-02-23 Cerulean Pharma Inc. Conjugates, particles, compositions, and related methods
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
IL315940A (en) 2015-07-28 2024-11-01 Univ Pennsylvania Altered monocytes/macrophages expressing chimeric antigen receptors and their uses
WO2020097193A1 (en) 2018-11-06 2020-05-14 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
US11026973B2 (en) 2019-04-30 2021-06-08 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
CN114981409A (zh) 2019-09-03 2022-08-30 美洛德生物医药公司 用于基因组整合的方法和组合物
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
EP4161536A4 (en) 2020-06-04 2024-08-14 Carisma Therapeutics Inc. Novel constructs for chimeric antigen receptors
EP4240367A4 (en) 2020-11-04 2024-10-16 Myeloid Therapeutics, Inc. MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
WO2022197949A2 (en) 2021-03-17 2022-09-22 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
BR112023023642A2 (pt) 2021-05-11 2024-01-30 Myeloid Therapeutics Inc Métodos e composições para integração genômica

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004832A1 (en) * 1995-07-25 1997-02-13 Massachusetts Institute Of Technology Enhanced transdermal transport using ultrasound
WO1998029134A2 (en) * 1996-12-31 1998-07-09 Altea Technologies, Inc. Microporation of tissue for delivery of bioactive agents
US5944710A (en) * 1996-06-24 1999-08-31 Genetronics, Inc. Electroporation-mediated intravascular delivery

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4293539A (en) * 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1994007367A1 (en) * 1992-09-29 1994-04-14 Apollon, Inc. Anti-viral oligomers that bind polypurine tracts of single-stranded rna or rna-dna hybrids
US5807306A (en) * 1992-11-09 1998-09-15 Cortrak Medical, Inc. Polymer matrix drug delivery apparatus
US5820879A (en) * 1993-02-12 1998-10-13 Access Pharmaceuticals, Inc. Method of delivering a lipid-coated condensed-phase microparticle composition
US5993434A (en) * 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5702359A (en) * 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US5439440A (en) * 1993-04-01 1995-08-08 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
EP0804249A2 (en) * 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6040295A (en) * 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
US5922253A (en) * 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
US5955096A (en) * 1996-06-25 1999-09-21 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
US5869326A (en) * 1996-09-09 1999-02-09 Genetronics, Inc. Electroporation employing user-configured pulsing scheme
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
US6261281B1 (en) * 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US6055453A (en) * 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6183746B1 (en) * 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6197229B1 (en) * 1997-12-12 2001-03-06 Massachusetts Institute Of Technology Method for high supercoiled DNA content microspheres
CA2345492C (en) * 1998-09-29 2009-12-22 Zars, Inc. Methods and apparatus for improved administration of pharmaceutically active compounds
ES2260291T3 (es) * 2000-09-28 2006-11-01 Chiron Corporation Microparticulas para la administracion de acidos nucleicos heterologos.
EP1352072A4 (en) * 2001-01-17 2004-09-01 Zycos Inc NUCLEIC ACID RELEASE PREPARATIONS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004832A1 (en) * 1995-07-25 1997-02-13 Massachusetts Institute Of Technology Enhanced transdermal transport using ultrasound
US5944710A (en) * 1996-06-24 1999-08-31 Genetronics, Inc. Electroporation-mediated intravascular delivery
WO1998029134A2 (en) * 1996-12-31 1998-07-09 Altea Technologies, Inc. Microporation of tissue for delivery of bioactive agents

Also Published As

Publication number Publication date
AU2003219805A1 (en) 2003-09-09
EP1482974A2 (en) 2004-12-08
WO2003070905A3 (en) 2004-01-15
CA2476452A1 (en) 2003-08-28
JP2005530695A (ja) 2005-10-13
US20040053873A1 (en) 2004-03-18
WO2003070905A2 (en) 2003-08-28
EP1482974A4 (en) 2006-08-02

Similar Documents

Publication Publication Date Title
AU2003219805B2 (en) Electroporation methods for introducing bioactive agents into cells
Hanagata Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system
AU2001268159B2 (en) Delivery systems for bioactive agents
Kasturi et al. Covalent conjugation of polyethyleneimine on biodegradable microparticles for delivery of plasmid DNA vaccines
Zhang et al. Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles
Beaudette et al. In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in acid-degradable microparticle vaccines
US20160220667A1 (en) Continuous cell programming devices
AU2001268159A1 (en) Delivery systems for bioactive agents
MXPA06012990A (es) Microesferas de acidos nucleicos, produccion y suministro de las mismas.
EA030813B1 (ru) Способы генерации антительного иммунного ответа и увеличения местной индукции иммунных цитокинов при использовании синтетических наноносителей, соединенных с адъювантами
EP1309904A1 (en) Improved poloxamer and poloxamine compositions for nucleic acid delivery
JP2009261411A (ja) 核酸を輸送するための微粒子
US20020182258A1 (en) Microparticles for delivery of nucleic acid
Li et al. Stability and release characteristics of poly (D, L-lactide-co-glycolide) encapsulated CaPi-DNA coprecipitation
JP2011088909A (ja) 核酸を送達するための微粒子
Zwiorek Gelatin nanoparticles as delivery system for nucleotide-based drugs
JP2002508751A (ja) ワクチン接種および遺伝子治療のためのマイクロカプセル化ｄｎａの作成方法
AU2005201927B2 (en) Microparticles for delivery of nucleic acid
WO2025217086A1 (en) Lnp fiber hydrogel composites and methods
US20190307704A1 (en) Method for enhanced delivery of gene based therapy and vaccination using electroporation
Wang Biodegradable polymer microparticles for genetic vaccine delivery
Lloyd Patent focus on drug delivery: June-November 1999
WO2001041810A2 (en) Nucleic acid delivery system
Barman et al. 13 Micro-and Nanoparticulate Polymeric Delivery Systems for Nucleic Acid-Based Medicine
Yamini Release studies of naked DNA, polyplexes and lipoplexes from polymeric films

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: EISAI CORPORATION OF NORTH AMERICA

Free format text: FORMER APPLICANT(S): MGI PHARMA BIOLOGICS, INC.

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: EISAI INC.

Free format text: FORMER OWNER WAS: EISAI CORPORATION OF NORTH AMERICA

MK14 Patent ceased section 143(a) (annual fees not paid) or expired